

Characteristics of included studies

Study	Study groups/number of participants	Mean doses (Range) (mg/days)	Trial duration (weeks)	Minimum Age	Mean Age	Diagnosis	Study design	Sponsors
Allard2004 (1)	Venlafaxine: n= 76 Citalopram: n= 75	V: 116 (75-150) C: 26 (20-30)	8	64	73,1	DSM-IV major depression	DB-RCT	Wyeth Elderly
Anon 2003 (2)	Nortriptyline: n= 34 Venlafaxine: n= 34	N: 62,5 (50-100) V: 251,47 (225-300)	26	65	70,83	DSM-IV unipolar major depression	SB-RCT	No sponsor stated
Bocksberger 1993 (3)	Fluvoxamine: n= 20 Moclobemide: n= 20	F: 172 (100-200) M: 433 (300-450)	4	65	74,45	DSM-III major depressive episode	DB-RCT	No sponsor stated
Brion 1996 (4)	Tianeptine: n= 209 Mianserin: n= 106	T: 31,25 (25-37,5) M: 30	26	70	78,53	DSM-III-R depression majeure	DB-RCT	No sponsor stated
Cassano 2002 (5)	Fluoxetine: n= 119 Paroxetine: n= 123	F: 20-66 P: 20-40	6	65	75,24	ICD-10 depression (paragraphs F32, F32.1 and F32.2)	DB-RCT	SmithKline Beecham
Chen 2011 (6)	Escitalopram: n= 29 Placebo n= 26	E: 10	8	65	68,9	DSM-IV major depression	DB-RCT	No sponsor stated
Cohn 1990 (7)	Sertraline: n= 161 Amitriptyline: n= 80	S: 116 (50-200) A: 88 (50-150)	8	63	70,33	DSM-III major depression or bipolar disorder	DB-RCT	No sponsor stated
Dorman 1992 (8)	Mianserin: n= 28 Paroxetine: n= 29	M: 60 P: 30	6	65	-	DSM-III unipolar depression	DB-RCT	No sponsor stated
EUCTR-001829-33-FR 2008 (9)	Placebo: n= 121 Duloxetine: n= 249	D: 60	12	65	72,89	DSM-IV-TR Major Depressive Disorder	DB-RCT	Eli Lilly
EUCTR-003821-25-DK 2005 (10)	Placebo: n= - Escitalopram: n= 99	E: 10	12	65	70,3	ICD-10 depressive single episode, depressive recurrent episode or organic depressive episode	DB-RCT	No sponsor stated
EUCTR-005612-26-SK 2013 (11)	Escitalopram: n= 99 Placebo: n= 107 Tianeptine: n= 105	E: 10 T: 25-50	8	65	70,44	DSM-IV-T Major Depressive Episode	DB-RCT	Institut de Recherches Internationales Servier
Finkel 1999a (12)	Sertraline: n= 39 Nortriptyline: n=37	S: 102 (50-150) N: - (25-100)	12	70	74,49	DSM-III-R major depression	DB-RCT	Pfizer

Finkel 1999b (13)	Fluoxetine: n= 33 Sertraline: n=42	F: 28,5 (20-40) S: 72,6 (50-100)	12	70	74,44	DSM-III-R major depression	DB-RCT	No sponsor stated
Geretsegger 1995 (14)	Paroxetine: n= 44 Amitriptyline: n= 47	P: 20-30 A: 100-150	6	65	71,15	DSM-III major depression	DB-RCT	SmithKline Beecham
GlaxoSmithKline 1991a (15)	Paroxetine: n=6 Clomipramine: n= 5	P: 20-40 C: 25-100	14	65	83,2	DSM-III major depressive episode	DB-RCT	Glaxo-Smith-Kline
GlaxoSmithKline 1991b (16)	Dothiepin: n= 67 Paroxetine: n= 67	D: 75 P: 20	6	65	75,85	DSM-III-R major depressive episode	DB-RCT	Glaxo-Smith-Kline
GlaxoSmithKline 1993 (17)	Paroxetine: n=57 Lofepramine: n= 49	P: 20-30 L: 70-320	8	65	75,27	DSM-III-R major depressive episode	DB-RCT	Glaxo-Smith-Kline
Guelfi 1999 (18)	Tianeptine: n= 115 Fluoxetine: n=122	T: 25-37,5 F: 20	12	65	77,56	DSM-III-R major depressive episode	DB-RCT	Eli-Lilly
Heun2013 (19)	Placebo: n= 71 Agomelatine: n=151	A: 25 50	8	65	71,84	DSM-IV-TR moderate to severe episode of recurrent MDD	DB-RCT	Servier
Hewett 2010 (20)	Placebo: n= 208 Bupropion: n= 212	B: 179 (150-300)	10	65	71,10	DSM-IV MDD	DB-RCT	Glaxo-Smith-Kline
Hutchinson 1992 (21)	Amitriptyline: n= 32 Paroxetine: n= 58	A: 100 P: 30	6	65	71,82	DSM-III major depressive disorder	DB-RCT	Glaxo-Smith-Kline
Jansen 2003 (22)	Nortriptyline/ paroxetine	N: 25-72 P: 10-20	4	71	82	DSM-IV with major depressive or dysthymic disorders	DB-RCT	No sponsor stated
Karlsson 2000 (23)	Citalopram: n= 163 Mianserin: n= 173	C: 28 (20-40) M: 40 (30-60)	12	64	75,17	DSM-III-R major depression	DB-RCT	No sponsor stated
Kasper2005 (24)	Fluoxetine: n= 164 Placebo: n= 180 Escitalopram: n= 174	F: 20 E: 10	8	65	75	DSM-IV MDD	DB-RCT	No sponsor stated
Katona 1999 (25)	Imipramine: n= 109 Reboxetine: n= 109	I: 50-100 R: 4-6	8	65	74,15	DSM-III-R MDD	DB-RCT	Pharmacia & Upjohn
Katona 2012 (26)	Duloxetine: n= 151 Vortioxetine: n= 156 Placebo: n= 145	D: 60 V: 5	8	65	70,57	DSM-IV MDD	DB-RCT	H. Lundbeck A/S
Kyle 1998 (27)	Citalopram: n= 179 Amitriptyline: n= 186	C: 24 (20-40) A: 57 (50-100)	8	65	73,76	DSM-III-R major depression	DB-RCT	H. Lundbeck A/S
Mahapatra 1997 (28)	Dothiepin: n= 48 Venlafaxine: n= 44	D: 50-150 V: 50-150	6	64	74	DSM-III-R major depression	DB-RCT	wyeth ayerst pharmaceuticals

Nair 1993 (29)	Doxepin: n= 19 Trimipramine: n= 18	D: 138 (100-200) T: 144 (100-200)	5	-	69,38	DSM-III Major Depressive Episode	DB-RCT	Rhone-Poulenc Rorer
NCT00130455 2006 (30)	Escitalopram/ Placebo	E: 5-10	12	65	-	ICD-10 single/recurrent / organic depressive episode	DB-RCT	Psychiatric Hospital, Hillerød
Newhouse 1995 (31)	Fluoxetine: n= 33 Sertraline: n= 42	F: 20-40 S: 50-100	12	70	74,4	DSM-III-R major depressive disorder	DB-RCT	Pfizer
Phanjoo 1991 (32)	Mianserin: n= 25 Fluvoxamine: n= 25	M: 60 (40-80) F: 170 (100-200)	6	66	76,5	DSM-III major depressive episode	DB-RCT	No sponsor stated
Rahman 1991 (33)	Fluvoxamine: n= 26 Dothiepin: n= 26	F: 157 (100-200) D: 159 (100-200)	6	61	74	DSM-III major depressive episode	DB-RCT	No sponsor stated
Raskin 2007 (34)	Placebo: n= 104 Duloxetine: n= 207	D: 60	8	65	72,86	DSM-IV recurrent major depressive disorder	DB-RCT	Eli Lilly
Robinson 2014 (35)	Duloxetine: n= 249 Placebo: n= 121	D: 60	12	65	73,04	DSM-IV-TR Major Depressive Disorder	DB-RCT	Eli Lilly
Roose 2004 (36)	Citalopram: n= 84 Placebo: n= 91	C: 10-40	8	75	79,59	DSM-IV unipolar depression, single or recurrent, nonpsychotic	DB-RCT	Forest
Schatzberg 2002 (37)	Mirtazapine: n= 128 Paroxetine: n= 126	M: 34 (15-45) P: 34 (20-40)	8	65	71,85	DSM-IV single or recurrent major depressive episode	DB-RCT	Organon Pharmaceuticals
Schatzberg 2006 (38)	Venlafaxine: n= 104 Placebo: n= 96 Fluoxetine: n= 100	V: 225 (75-225) F: - (20-60)	8	65	71	DSM-IV unipolar depression (single or recurrent, nonpsychotic)	DB-RCT	Wyeth Research
Schifano 1990 (39)	Mianserin: n= 25 Maprotiline: n= 23	Mi: 67,6-90 Ma: 112,5-150	4	65	75,41	DSM-III a major depressive episode	DB-RCT	No sponsor stated
Schoene 1993 (40)	Fluoxetine: n= 52 Paroxetine: n= 54	F: 20-60 P: 20-40	6	61	74,01	DSM-III-R current episode of major depression	DB-RCT	No sponsor stated
Schweizer 1998 (41)	Imipramine: n=60 Buspirone: n= 57 Placebo: n= 60	I: 89 (25-150) B: 38 (10-60)	8	65	72	DSM-III-R unipolar major depression	DB-RCT	Bristol-Myers Squibb
Smeraldi 1997 (42)	Venlafaxine: n= 55 Clomipramine: n= 58 Trazodone: n= 57	V: 75-150 C: 50-100 T: 150-300	6	65	71	DSM-III-R major depression	DB-RCT	No sponsor stated
Study 032a (43)	Reboxetine: n= 24 Placebo: n= 26	R: 4-6	8	63	79,96	DSM-III-R Major Depressive Disorder not accompanied by	DB-RCT	No sponsor stated

						psychotic features		
Tignol 1998 (44)	Imipramine: n= 107 Milnacipran: n= 112	I: 75-100 M: 75-100	8	65	74,10	DSM-III-R MDE with or without melancholia and without psychotic features	DB-RCT	No sponsor stated

DB-RCT: Double-Blind Randomized Trial, SB-RCT: Single-Blind Randomized Trial, DSM: Diagnostic and Statistical Manual of Mental Disorders, ICD: International Statistical Classification of Diseases and Related Health Problems

References

1. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. *International journal of geriatric psychiatry* 2004; 19(12):1123–30.
2. Anon. Venlafaxine and nortriptyline similar in depression. *Brown University Geriatric Psychopharmacology Update* 2003; 7(3):7.
3. Bocksberger JP, Gachoud JP, Richard J, Dick P. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. *European psychiatry* 1993; 8(6):319–24.
4. Brion S, Audrain S, Bodinat C de. Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin. *Presse medicale (Paris, France : 1983)* 1996; 25(9):461–8.
5. Cassano GB, Puca F, Scapicchio PL, Trabucchi M, Italian Study Group on Depression in Elderly, Patients. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. *Journal of clinical psychiatry* 2002; 63(5):396–402.
6. Chen YM, Huang XM, Thompson R, Zhao YB. Clinical features and efficacy of escitalopram treatment for geriatric depression. *Journal of international medical research* 2011; 39(5):1946–53.
7. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. *Journal of clinical psychiatry* 1990; 51 Suppl B(Suppl B):28–33.
8. Dorman T. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. *Int Clin Psychopharmacol* 1992; 6 Suppl 4(Suppl 4):53–8.
9. EUCTR-001829-33-FR. Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression - HMFA: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001829-33; 2008.
10. EUCTR-003821-25-DK. A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients. - Double-blind placebo controlled study of escitalopram in the treatment of depression in

the elderly: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003821-25; 2005.

11. EUCTR-005612-26-SK. Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005612-26; 2013.

12. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. *International psychogeriatrics / IPA* 1999; 11(1):85–99.

13. Finkel SI, Richter EM, Clary CM, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. *American journal of geriatric psychiatry* 1999; 7(3):221–7.

14. Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicentre double-blind study of paroxetine and amitriptyline in elderly depressed inpatients. *Psychopharmacology* 1995; 119(3):277–81.

15. GlaxoSmithKline. A Double Blind Comparative Study of the Effects of Paroxetine and Clomipramine on Cognitive Function in Elderly Patients with Major Depression. GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com] 1991.

16. GlaxoSmithKline. A double-blind, between patient, multicentre study in general practice comparing the efficacy and tolerability of paroxetine with those of dothiepin in the treatment of elderly depressed patients. GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com] 1991.

17. GlaxoSmithKline. A Double-Blind, Multicentre Study Comparing the Efficacy, Tolerability and Effects on Cognitive Function of Paroxetine With Those of Lofepamine in Elderly Depressed Hospital In- or Out-Patients. GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com] 1993.

18. Guelfi JD, Bouhassira M, Bonett-Perrin E, Lancrenon S. Study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients, followed in general practice. *Encephale* 1999; 25(3):265–70.

19. Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study [ISRCTN57507360]. *Journal of clinical psychiatry* 2013; 74(6):587–94.

20. Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD et al. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. *Journal of psychopharmacology (Oxford, England)* 2010; 24(4):521–9. Available from: URL: <https://clinicaltrials.gov/ct2/show/NCT00093288>.

21. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. *International clinical psychopharmacology* 1992; 6 Suppl 4(Suppl 4):43–51.

22. Jansen RW, Mehagnoul-Schipper D, Hulsbos P, Jellesma-Eggenkamp M, Hoefnagels W. Effect of paroxetine and nortriptyline on orthostatic and postprandial hypotension in patients 70 years of age with depressive disorders [conference presentation]. *International Psychogeriatrics* [abstracts from

The International Psychogeriatric Association Eleventh International Congress Chicago, United States 17-22 August 2003] 2003; 15(Suppl 2).

23. Karlsson I, Godderis J, Augusto De Mendonca Lima, C., Nygaard H, Simanyi M, Taal M et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. *International journal of geriatric psychiatry* 2000; 15(4):295–305.

24. Kasper S, Swart H de, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. *American journal of geriatric psychiatry* 2005; 13(10):884–91.

25. Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. *J Affect Disord* 1999; 55(2-3):203–13.

26. Katona C, Hansen T, Olsen CK. A randomised, double-blind, placebocontrolled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. *European neuropsychopharmacology* 2012; 22:S258-S259.

27. Kyle CJ, Petersen H, Hopfner E. Citalopram treats major depression in the elderly without causing anticholinergic side-effects. XX1st Collegium Internationale Neuro Psychopharmacologicum, Glasgow, Scotland. 12th 16th July, 1998. 1998.

28. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. *International journal of clinical practice* 1997; 51(4):209–13.

29. Nair NP, Amin M, Schwartz G, Dastoor D, Thavundayil JX, Mirmiran J et al. A comparison of the cardiac safety and therapeutic efficacy of trimipramine versus doxepin in geriatric depressed patients. *Journal of the American Geriatrics Society* 1993; 41(8):863–7.

30. NCT00130455. Treatment of Depression in the Elderly:
<https://ClinicalTrials.gov/show/NCT00130455>; April April. Available from: URL:
<https://ClinicalTrials.gov/show/NCT00130455>.

31. Newhouse P, Finkel S, Richter E. SSRIs in the treatment of depressed out patients aged 70 years and older. 8th ECNP (European College of Neuropsychopharmacology) Congress, Venice, Italy 1995.

32. Phanjo AL, Wonnacott S, Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. *Acta psychiatrica Scandinavica* 1991; 83(6):476–9.

33. Rahman MK, Akhtar MJ, Savla NC, Sharma RR, Kellett JM, Ashford JJ. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. *British journal of clinical practice* 1991; 45(4):255–8.

34. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. *American journal of psychiatry* 2007; 164(6):900–9.

35. Robinson M, Oakes TM, Raskin J, Liu P, Shoemaker S, Nelson JC. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. *American journal of geriatric psychiatry* 2014; 22(1):34–45.

36. Roose SP, Sackeim HA, Krishnan KR, Pollock BG, Alexopoulos G, Lavretsky H et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. *American journal of psychiatry* 2004; 161(11):2050–9.
37. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Mirtazapine vs. Paroxetine Study, Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. *American journal of geriatric psychiatry* 2002; 10(5):541–50.
38. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. *American journal of geriatric psychiatry* 2006; 14(4):361–70.
39. Schifano F, Garbin A, Renesto V, Dominici MG de, Trinciarelli G, Silvestri A et al. A double-blind comparison of mianserin and maprotiline in depressed medically ill elderly people. *Acta psychiatrica Scandinavica* 1990; 81(3):289–94.
40. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. *Journal of clinical psychopharmacology* 1993; 13(6 Suppl 2):34S-39S.
41. Schweizer E, Rickels K, Hassman H, Garcia-Espana F. Buspirone and imipramine for the treatment of major depression in the elderly. *Journal of clinical psychiatry* 1998; 59(4):175–83.
42. Smeraldi E, Aguglia A, Cattaneo M, Cerati C, Covelli C, Del Zompo M et al. Double-blind, randomized study of venlafaxine, clomipramine, and trazodone in geriatric patients with major depression. 10th European College of Neuropsychopharmacology Congress. Vienna, Austria. 13th 17th September 1997. 1997.
43. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. study032a 1995.
44. Tignol J, Pujol-Domenech J, Chartres JP, Leger JM, Pletan Y, Tonelli I et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. *Acta psychiatrica Scandinavica* 1998; 97(2):157–65.